Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia (CML) patients who do not respond well to tyrosine ...

US regulators’ use of a speedy clearance pathway for a new frontline indication for asciminib for chronic myeloid leukemia (CML) has raised questions due to the number of medications already available ...

Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...

CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...

Preclinical data shows TERN-701's superior potency against CML resistance mutations; early clinical trial results indicate promising patient responses. Terns Pharmaceuticals announced promising ...

The metastasis suppressor 1 (Mtss1) protein acts a tumour suppressor in chronic myeloid leukaemia (CML) stem cells, reveals research published in Leukemia. Using a double transgenic mouse model of CML ...

Assessment of long-term toxicities of imatinib in CML: Experience from a tertiary care cancer centre in south India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...